Prothena Corporation PLC (PRTA) Position Boosted by Westfield Capital Management Co. LP

Westfield Capital Management Co. LP increased its position in shares of Prothena Corporation PLC (NASDAQ:PRTA) by 186.0% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 684,160 shares of the biotechnology company’s stock after purchasing an additional 444,966 shares during the period. Westfield Capital Management Co. LP owned approximately 1.80% of Prothena Corporation PLC worth $37,027,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Bank of Montreal Can boosted its stake in shares of Prothena Corporation PLC by 6.7% during the 2nd quarter. Bank of Montreal Can now owns 1,858 shares of the biotechnology company’s stock worth $100,000 after purchasing an additional 117 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of Prothena Corporation PLC by 187.5% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,375 shares of the biotechnology company’s stock worth $129,000 after purchasing an additional 1,549 shares during the period. Ameritas Investment Partners Inc. purchased a new position in shares of Prothena Corporation PLC during the 1st quarter worth about $167,000. Sei Investments Co. purchased a new position in shares of Prothena Corporation PLC during the 2nd quarter worth about $176,000. Finally, SG Americas Securities LLC boosted its stake in shares of Prothena Corporation PLC by 16.2% during the 2nd quarter. SG Americas Securities LLC now owns 4,064 shares of the biotechnology company’s stock worth $220,000 after purchasing an additional 568 shares during the period.

Prothena Corporation PLC (NASDAQ PRTA) traded down 0.80% during midday trading on Monday, hitting $64.23. 15,104 shares of the stock traded hands. Prothena Corporation PLC has a 12-month low of $40.58 and a 12-month high of $69.53. The company’s 50-day moving average is $59.45 and its 200 day moving average is $56.23. The firm’s market cap is $2.46 billion.

Prothena Corporation PLC (NASDAQ:PRTA) last announced its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.46) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.89) by $0.43. The company had revenue of $26.81 million during the quarter, compared to analyst estimates of $16.08 million. Prothena Corporation PLC had a negative net margin of 527.56% and a negative return on equity of 33.20%. Prothena Corporation PLC’s revenue was up 7951.1% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.18) earnings per share. On average, analysts anticipate that Prothena Corporation PLC will post ($4.39) EPS for the current fiscal year.

In other news, insider Karin L. Walker sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, July 17th. The shares were sold at an average price of $64.89, for a total value of $324,450.00. Following the completion of the transaction, the insider now owns 5,000 shares of the company’s stock, valued at $324,450. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Dennis J. Selkoe sold 3,500 shares of the firm’s stock in a transaction that occurred on Friday, July 7th. The shares were sold at an average price of $58.11, for a total transaction of $203,385.00. Following the completion of the transaction, the director now directly owns 6,345 shares of the company’s stock, valued at approximately $368,707.95. The disclosure for this sale can be found here. Company insiders own 3.10% of the company’s stock.

A number of research firms recently commented on PRTA. BidaskClub raised shares of Prothena Corporation PLC from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, July 19th. Royal Bank Of Canada began coverage on shares of Prothena Corporation PLC in a research report on Thursday. They issued an “outperform” rating and a $87.00 price objective for the company. ValuEngine raised shares of Prothena Corporation PLC from a “sell” rating to a “hold” rating in a research report on Friday, September 1st. Jefferies Group LLC began coverage on shares of Prothena Corporation PLC in a research report on Monday, July 10th. They issued a “buy” rating and a $100.00 price objective for the company. Finally, Evercore ISI began coverage on shares of Prothena Corporation PLC in a research report on Wednesday, August 16th. They issued an “outperform” rating and a $83.00 price objective for the company. One investment analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Prothena Corporation PLC has a consensus rating of “Buy” and an average price target of $78.31.

TRADEMARK VIOLATION WARNING: “Prothena Corporation PLC (PRTA) Position Boosted by Westfield Capital Management Co. LP” was originally reported by Transcript Daily and is owned by of Transcript Daily. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://transcriptdaily.com/2017/09/18/prothena-corporation-plc-prta-position-boosted-by-westfield-capital-management-co-lp.html.

Prothena Corporation PLC Profile

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Want to see what other hedge funds are holding PRTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Prothena Corporation PLC (NASDAQ:PRTA).

Institutional Ownership by Quarter for Prothena Corporation PLC (NASDAQ:PRTA)

Receive News & Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply